Lobbying Information
Subject Matters
- Aboriginal Affairs
- Agriculture
- Arts and Culture
- Broadcasting
- Constitutional Issues
- Consumer Issues
- Defence
- Education
- Employment and Training
- Energy
- Environment
- Financial Institutions
- Fisheries
- Forestry
- Government Procurement
- Health
- Immigration
- Industry
- Infrastructure
- Intellectual Property
- Internal Trade
- International Relations
- International Trade
- Justice and Law Enforcement
- Labour
- Mining
- Regional Development
- Science and Technology
- Small Business
- Sports
- Taxation and Finance
- Telecommunications
- Tourism
- Transportation
Subject Matter Details
Legislative Proposal, Bill or Resolution
- Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry
- Canada's Food and Consumer Safety Action Plan as it relates to the regulation and protection of biopharmaceutical products.
- Income Tax Act as it relates to biopharmaceutical products
- Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
Legislative Proposal, Bill or Resolution, Regulation
- Canadian Environmental Protection Act and Regulationsin respect of modern science-based regulations to reflect rapidly changing new technologies.
- Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals.
Policies or Program
- Anti-Counterfeit Trade Agreement (ACTA) as it concerns counterfeit drugs
- Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease
- Canada-United States Regulatory Cooperation Council (RCC) initiatives related to the regulation of biopharmaceutical products
- Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships
- Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework
- Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH)
- Free trade treaty agreement as it relates to the North American Free Trade Agreement (NAFTA) and free trade negotiations as it relates to Columbia, India, and the European Union
- Pharmaceutical pricing policy arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
- Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits
- Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations
- The government's Science and Technology Strategy potential policies & programs pertaining to the biopharmaceutical industry
- World Health Organization (WHO) issues concerning pharmaceuticals as it relates to Counterfeits, Access to Medicines, and the Intergovernmental Working Group (IGWG)
- World Intellectual Property Organization (WIPO) issues concerning the protection of and access to intellectual property
- World Trade Organization (WTO) issues concerning the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility"
Regulation
- Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products
- Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry
- New Substances Notification Regulations as it relates to the biopharmaceutical industry
- Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
- Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive
- Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products
- Smart Regulations as it relates to the biopharmaceutical industry
Communication Techniques
-
Written communication
-
Oral communication
The lobbyist has arranged or expects to arrange one or more meetings on behalf of the client between a public office holder and any other person in the course of this undertaking.
Government Institutions
-
Agriculture and Agri-Food Canada (AAFC)
-
Canada Revenue Agency (CRA)
-
Canadian Institutes of Health Research (CIHR)
-
Canadian International Trade Tribunal (CITT)
-
Competition Tribunal (CT)
-
Employment and Social Development Canada (ESDC)
-
Environment and Climate Change Canada (ECCC)
-
Finance Canada (FIN)
-
Fisheries and Oceans Canada (DFO)
-
Global Affairs Canada (GAC)
-
Health Canada (HC)
-
Innovation, Science and Economic Development Canada (ISED)
-
Justice Canada (JC)
-
Members of the House of Commons
-
National Research Council (NRC)
-
Natural Resources Canada (NRCan)
-
Natural Sciences and Engineering Research Council (NSERC)
-
Office of the Information and Privacy Commissioner (OIPC)
-
Patented Medicine Prices Review Board (PMPRB)
-
Prime Minister's Office (PMO)
-
Privy Council Office (PCO)
-
Public Health Agency of Canada (PHAC)
-
Public Prosecution Service of Canada (PPSC)
-
Public Safety Canada (PS)
-
Public Services and Procurement Canada (PSPC)
-
Senate of Canada
-
Statistics Canada (StatCan)
-
Treasury Board Of Canada Secretariat (TBS)
-
Veterans Affairs Canada (VAC)
Client Details
Government funding
No government funding was received during the last completed financial year.
Client Contact Information
Address:
1220-55 Metcalfe St.
Ottawa, ON K1P 6L5
Canada
Telephone number:
613-236-0455
Fax number:
613-236-7919
Client representative
Kathleen Sullivan, Executive Director, Innovation and National Policies
Parent Company Information
Innovative Medicines Canada / Médicaments novateurs Canada is not a subsidiary of any other parent companies.
Coalition Members Information
Innovative Medicines Canada / Médicaments novateurs Canada is not a coalition.
Individual, organization or corporation with a Direct Interest Beneficiary Information
The activities of Innovative Medicines Canada / Médicaments novateurs Canada are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
Subsidiary Beneficiary Information
Innovative Medicines Canada / Médicaments novateurs Canada does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyist Details
ANDRE ALBINATI
|
Public offices held
Business address:
Suite 200, 46 Elgin Street
OTTAWA, ON K1P 5K6
Canada
Telephone number:
613-563-4455
Fax number:
613-236-6173
Consultant Firm and Address
Firm:
Earnscliffe Strategy Group
Address:
Suite 200, 46 Elgin Street
OTTAWA, ON K1P 5K6
Canada
Telephone number:
613-563-4455
Fax number:
613-236-6173
